In addition, the porcine renal tissue/plasma concentration ratio of endogenous Ang II decreased by Ϸ90% after eprosartan pretreatment, 3 thus confirming that renal 125 I-Ang II accumulation fully resembles that of endogenous Ang II.
On the Origin of Urinary Angiotensin II

To the Editor:
With great interest we read the publication by Shao et 4 In addition, the porcine renal tissue/plasma concentration ratio of endogenous Ang II decreased by Ϸ90% after eprosartan pretreatment, 3 thus confirming that renal 125 I-Ang II accumulation fully resembles that of endogenous Ang II.
In the study by Shao et al, 1 the renal tissue/plasma ratio of endogenous Ang II decreased by Ͼ90% after candesartan treatment (from 358/24 to 21/157), identical to our results in pigs. Yet, the ratio of Val 5 -Ang II was virtually unchanged after candesartan treatment (385/283 versus 242/217). This demonstrates that the renal accumulation of Val 5 -Ang II, unlike that of Ang II and 125 I-Ang II, largely occurs in an AT 1 receptorindependent manner, at least when infused at a rate of 80 ng/min. One explanation for this discrepancy may be that this rate is above the rate required to obtain (near) complete renal AT 1 receptor occupancy. In agreement with this concept, Val 5 -Ang II suppressed plasma renin activity by Ͼ95%. Yet, endogenous plasma Ang II was either unaltered 1 or increased. 5 According to Figure 6 , 1 urinary Val 5 -Ang II excretion without candesartan amounted to 3 to 7 pmol/24 hours. Urinary volumes ranged from 11 to 38 mL/24 hours, and thus the urinary Val 5 -Ang II concentrations were 80 to 636 fmol/mL. This equals the Val 5 -Ang II concentration range in plasma. Because Val 5 -Ang II cannot be made in the kidney, and assuming that circulating Val 5 -Ang II reaches urine to the same degree as circulating Ang II, it appears that urine minimally contains the same Ang II levels as plasma based on filtration and/or tubular secretion of circulating Ang II. Consequently, by using the Val 5 -Ang II urine/plasma concentration ratio, it should be possible to distinguish plasma-and kidney-derived Ang II in urine. The same procedure might be followed during candesartan treatment so that one gets an indication of the AT 1 receptor blockade-induced changes in the urinary washout of circulating Ang II and renal Ang II. Given the identical urinary excretion rates of Val 5 -Ang II and Ang II during candesartan treatment, as well as their comparable plasma levels during such treatment, it can already be predicted that candesartan reduces the net release of Ang II from renal tissue sites into urine to 0.
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